Humanigen Executives Charged with Insider Trading in the US
In the latest development in a year filled with insider trading charges among biopharma companies, the U.S. Securities and Exchange Commission (SEC) announced on December 30th that it had taken action against two high-ranking executives at Humanigen Inc. for trading based on non-public information regarding FDA decisions.
This news comes as part of an ongoing effort by regulatory authorities to crack down on insider trading within the healthcare industry.
The SEC’s complaint alleges that the executives used their knowledge of forthcoming FDA actions to make advantageous trades, putting them in violation of securities laws.
This serves as a reminder of the importance of maintaining integrity and transparency in financial transactions, especially within the highly regulated biopharma sector.
As always, it is crucial for individuals in positions of influence to adhere to ethical standards and follow all regulations to ensure fair and transparent financial markets.
